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Abstract Congenital heart disease (CHD) has become the
leading risk factor for pediatric infective endocarditis (IE) in
developed countries after the decline of rheumatic heart
disease. Advances in catheter- and surgery-based cardiac
interventions have rendered almost all types of CHD
amenable to complete correction or at least palliation. Patient
survival has increased, and a new patient population, referred
to as adult CHD (ACHD) patients, has emerged. Implanted
prosthetic material paves the way for cardiovascular device-
related infections, but studies on the management of CHD-
associated IE in the era of cardiovascular devices are scarce.
The types of heart malformation (unrepaired, repaired,
palliated) substantially differ in their lifetime risks for IE.
Streptococci and staphylococci are the predominant patho-
gens. Right-sided IE is more frequently seen in patients with
CHD. Relevant comorbidity caused by cardiac and extrac-
ardiac episode-related complications is high. Transesophageal
echocardiography is recommended for more precise visuali-
zation of vegetations, especially in complex type of CHD in
ACHD patients. Antimicrobial therapy and surgical manage-
ment of IE remain challenging, but outcome of CHD-
associated IE from the neonate to the adult is better than in
other forms of IE. Conclusion: Primary prevention of IE is
vital and includes good dental health and skin hygiene;
antibiotic prophylaxis is indicated only in high-risk patients
undergoing oral mucosal procedures.
Keywords Infective endocarditis . Congenital heart
disease . Cardiac surgery. Interventional cardiology.
Echocardiography. Blood culture
Abbreviations
ACHD Adult with congenital heart disease
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ASD Atrial septal defect
ASDOS Atrial septal defect occlusion system
AV Aortic valve
CHD Congenital heart disease
CHF Congestive heart failure
CI Confidence interval
CoA Coarctation of the aortic arch
ESC European Society of Cardiology
HACEK Haemophilus aphrophilus, Actinobacillus acti-
nomycetemcomitans, Cardiobacterium hominis,
Eikenella corrodens, and Kingella kingae
HLHS Hypoplastic left heart syndrome
IE Infective endocarditis
IVDA Intravenous drug abuser
LA Left atrium
LPA Left pulmonary artery
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MV Mitral valve
NBTE Nonbacterial thrombotic endocarditis
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PA Pulmonary artery
PDA Patent ductus arteriosus
PFO Patent foramen ovale
Pst Pulmonary valve stenosis
PV Pulmonary valve
PVA Perivalvular abscess
RA Right atrium
RHD Rheumatic heart disease
RV Right ventricle
SAS Subaortic stenosis
3rd gen 3rd generation
TEE Transesophageal echocardiography
TTE Transthoracic ecocardiography
TV Tricuspid valve
VSD Ventricular septal defect
Introduction
Congenital heart disease (CHD) has become largely manage-
able in developed countries in the last two decades, and a large
number of children with CHD survived until adulthood [19].
They have a completely repaired or, at least, palliated CHD,
and are referred to as adult CHD (ACHD) patients or as
grown up with CHD patients [37]. Improved medical and
surgical approaches and use of prosthetic materials made this
possible. Nevertheless, prosthetic material increases the risk
of associated infections, and infective endocarditis (IE)
remains one of the most feared complications of CHD [46].
Here, we review the clinical entity of CHD-associated
IE. Databases PubMed/Medline, EMBASE.com, and web
of science were searched for English language articles with
mesh terms “endocarditis” and “congenital heart disease,”
between 1960 and 2007. We considered articles reporting
more than 25 IE cases and providing information on cardiac
diagnoses or procedures performed. A systematic meta-
analysis of data was not possible because studies published
to date are underpowered and retrospective.
Epidemiology
The incidence of IE in adults varies between 1.5 and six cases
per 100,000 persons per year [22]. Men are affected at least
twice as often as women [77]. In 11% to 13%, an underlying
CHD is found [125, 126]. In children, incidence of IE is
considerably lower with 0.34 to 0.64 cases per 100,000
children per year [34, 43, 110] and male-to-female ratio is
1.2:1 [1, 8, 9, 20, 21, 33, 34, 38, 42, 47, 58, 65, 67, 68, 72,
74, 79, 83, 84, 88, 97, 99, 100, 107, 108, 110, 111, 116, 119,
122, 127, 137]. We reviewed 32 original articles reporting
2,361 IE episodes in 2,298 patients during an observation
time of 43,426 patient-years [1, 8, 9, 20, 21, 33, 34, 38, 42,
47, 58, 65, 67, 68, 72, 74, 79, 83, 84, 88, 97, 99, 100, 107,
108, 110, 111, 116, 119, 122, 127, 137]. Reports originated
from 15 countries and were retrospective single-center
reviews except three multi-center studies [34, 65, 97].
Thirteen studies included ACHD patients (age >18 years)
[9, 33, 34, 38, 65, 68, 72, 74, 83, 97, 122, 127, 137].
Figure 1 shows occurrence of IE between 1930 and 2004 in
Fig. 1 Frequency and overall mortality of IE in CHD are shown in the
context of the available antibiotic treatment and milestones of surgical
and interventional catheter therapy. Mean values were compiled from
retrospective clinical studies with at least 25 patients [1, 8, 9, 20, 21, 33,
34, 38, 42, 47, 53, 58, 65, 67–69, 72, 74, 79, 83, 84, 88, 97, 99, 100,
107, 108, 110, 111, 116, 119, 122, 127, 137]. 3rd gen indicates 3rd
generation, ASD atrial septal defect, HLHS hypoplastic left heart
syndrome, IE infective endocarditis, PDA patent ductus arteriosus, Pst
pulmonary valve stenosis, VSD ventricular septal defect
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the context of milestones of antibiotic treatment, cardiac
surgery, and interventional catheter therapy. Mean age at
diagnosis of IE in pediatric patients was 10.3 years, with a
bimodal age distribution with peaks during infancy and late
teenage years [36]. Mean age of IE in ACHD patients ranged
between 28 and 33 years, with a male-to-female ratio of 1.5
to 1 [38, 65, 97]. Around 4% of admissions to a ACHD-
specialized unit were aimed for workup of IE, and recently,
the frequency of adult-onset IE is 2.3% in ACHD patients
[83, 128]. The proportion of nonvalvular cardiovascular
device-related infections was as high as 5% [117].
Pathogenesis
CHD-associated IE results from complex interactions
between valvular or mural endocardium and endothelium,
blood components, circulating pathogens, and host defense
mechanisms, similar to IE in structural heart disease [24].
The steps include (1) damage of valvular or mural
endocardium, which exposes underlying matrix proteins to
thromboplastin and tissue factors resulting in (2) develop-
ment of nonbacterial thrombotic endocarditis (NBTE)
following platelet and fibrin deposition, (3) microbial
adherence to thrombi leading to (4) microbial colonization,
invasion, and replication within lesions of thrombotic
endocarditis, and (5) embolization of areas affected by
microbial thrombotic endocarditis (Table 1).
Cyanosis in complex types of CHD before surgery and use
of prosthetic material including palliative shunts, conduits, or
other cardiovascular devices increase the IE risk [24, 134].
Mechanisms of cyanosis on the pathogenesis of IE are not
clear.
Physical and chemical characteristics of prosthetic
material, pathogen virulence factors, and host responses
contribute to pathogenesis of (non)valvular cardiovascular
device-related infections (Fig. 2) [11]. Prosthetic material
with higher surface tension (polyethylene terephthalate)
exhibits higher binding capacity for fibrinogen, a hydrated
macromolecule [11], than material with lower surface
tension (fluorocarbon polymers) and, thus, is more prone
to initiate cardiovascular device-related infections. Key
pathogenetic steps are binding of fibrinogen to prosthetic
material and subsequent platelet aggregation. Pathogen
factors include tissue and foreign body adherence mole-
cules and foreign body surface biofilm formation [41].
Immediate host response to devices is mainly determined
by induced alteration of intravascular/intracardiac laminar
blood flow [115]. Shear stress of the endothelium by
turbulent flow alters cell shape, changes cytoskeletal
organization, and increases leukocytes and bacteria adhe-
sion to the endothelium [76, 114, 115]. Notably, cardiovas-
cular devices induce more chronic immune-mediated
healing responses during endothelialization in the 6 months
following implantation (Fig. 2) [5, 75].
Rheumatic heart disease (RHD) or CHD seem to be key
for pathogenesis of IE in children. Nevertheless, in infants
with intravascular catheters, NBTE de novo may contribute
to affection of right-sided heart structures, similar to IE in
intravenous drug abusers [95]. Epidemiologic studies on
pediatric IE show a trend toward a higher proportion of
children lacking pre-existing endocardial pathology in the
past decade [36].
Predisposing risk factors
The type of heart malformation as the substrate of valvular,
mural, or vascular damage and the source of bacteremia
predispose for IE [24, 70, 134].
Fig. 2 Pathogenesis
of cardiovascular device-related
infections: catheter interventional
closure of a membranous ventric-
ular septal defect with a medical
device as an example for foreign
material
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Type of heart malformation
Today, the incidence of RHD in industrialized countries is <10
per 100,000 children/year compared to up to 500 per
100,000 children/year in developing countries [27]. CHD
became the major risk factor for IE in children in
industrialized countries between 1950 and 1980, when
RHD as predisposing factor decreased from 29% to <4%
[1, 8, 9, 20, 21, 33, 34, 38, 42, 47, 58, 65, 67, 68, 72, 74, 79,
83, 84, 88, 97, 99, 100, 107, 108, 110, 111, 116, 119, 122,
127, 137].
The 2007 American Heart Association (AHA) guidelines
regarding prevention of IE distinguish unrepaired CHD
(with or without cyanosis), repaired CHD in biventricular
malformations (with complete or incomplete repair with
residual defects), and palliated CHD with functionally
univentricular malformation (often by using prosthetic
material) [134]. The lifetime risk for IE in unrepaired
cyanotic CHD is up to 8.2 cases per 1,000 patients/year [32,
53] compared to the cumulative incidence of IE in repaired
CHD during a 25-year follow-up after cardiac surgery of
0% after closure of secundum type atrial septal defect
(ASD) to 13% after repair of aortic valve stenosis [96, 134].
Risk assessments of the three types of CHD for IE are
hampered by simultaneous changes in the management of
CHD (Fig. 1). Most types of CHD have become treatable
either by repair or palliation. The number of unrepaired
CHD decreased due to cardiac surgery or catheter-related
cardiac interventions at younger age, whereas the number
of complex type CHD palliated by Fontan procedure
increased and patients may survive until adulthood
(Fig. 1) [66].
Unrepaired CHD
Unrepaired cyanotic CHD associates with a higher lifetime
risk for IE (8.2 cases per 1,000 patient-years) than
unrepaired non-cyanotic CHD or repaired cyanotic CHD
(ventricular septal defect 2.4 cases, repaired tetralogy of
Fallot 2.3, aortic valve stenosis 2.0, or atrioventricular
septal defect 1.7 per 1,000 patient-years) [32, 53]. The ratio
of unrepaired cyanotic to non-cyanotic CHD of around 1:2
[65, 83, 108, 110, 111, 116] is comparable to that of
cyanotic to non-cyanotic CHD in children [63].
Ventricular septal defect (VSD) is the most frequent
CHD and, if unrepaired, the most frequent CHD associated
with IE (Fig. 3) [83]. The incidence of IE in unrepaired
VSD is 1.5 to 2.4 per 1,000 patient-years, especially if
associated with aortic insufficiency or with left ventricle-to-
right atrial shunt [32, 53]. For an ACHD patient with
unrepaired VSD, the estimated lifetime risk for IE at age
30 years is 9.7% and by the end of life is 12% [52, 112]. In
patent ductus arteriosus, atrioventricular septal defect, and
ASD, IE is by far less frequent (Fig. 3). Whether complete
closure of VSD is needed to control lifetime risk for IE
requires careful individual risk–benefit analysis.
The second CHD most frequently associated with IE are
outflow tract obstructions [83]. Estimated risks are 0.2%
per 1,000 patient-years in native pulmonary stenosis
compared to 1.8% in aortic valve stenosis [51, 52, 60].
Right ventricle outflow tract may be affected in malforma-
tions, such as tetralogy of Fallot, pulmonary atresia with or
without VSD, and, less frequently, isolated pulmonary
valve stenosis. The left ventricle may be affected in aortic
valve diseases, including bicuspid aortic valve and coarc-
tation of aortic arch (Fig. 3). Nevertheless, ACHD patients
with left ventricular outflow tract obstructions seem to
show a tendency toward developing IE more frequently
than patients with VSD in the last two decades [52, 83].
This may be explained by the circumstance that residual
hemodynamic lesions after surgery of left ventricular
outflow tract obstructions are frequent, while complete
closure of VSD may abolish the IE risk entirely [60, 134].
The anatomic location of IE in CHD differs from that in
structural heart disease (Table 1) [1, 8, 9, 20, 21, 33, 34, 38,
42, 47, 53, 58, 65, 67–69, 72, 74, 79, 83, 84, 88, 97, 99,
107, 108, 110, 111, 116, 119, 122, 127, 137]. IE in CHD
affects left heart structures (mitral valve>aortic valve) in
around half of all cases (Fig. 3). The large proportion of
affected right heart structures in CHD (one third of all
cases) is the most striking difference compared to the
structural heart disease (<5% of all cases). Notably,
tricuspid valves are twice as frequently affected than
pulmonary valves (Fig. 3). While valvular endocardium is
predominantly involved in left-sided IE in patients with
CHD, right-sided IE may also affect mural structures of the
right ventricular wall such as surrounding VSD opening
and at counterpoint VSD jet stream at the lateral wall [72].
Nevertheless, extracardiac structures including pulmonary
artery, aortic arch, or systemic veins may also be involved
in CHD patients [78]. The right heart is more prone to
cardiovascular device-related infections than left heart [52,
96, 99], likely due to hemodynamic factors such as lower
oxygen saturation or low pressure conditions (Table 2)
[129].
Repaired CHD
Surgical or catheter interventional complete repair of CHD
with sufficient endothelialization after 6 months may reduce
risk for IE to that of healthy children, but the risk after
incomplete repair with residual defects may not do so, [8,
33, 34, 38, 51, 53, 58, 60, 65, 69, 72, 79, 83, 84, 88, 97,
108, 119, 137]. The calculated ratio of post-interventional
IE in repaired CHD (41%) compared to IE in unrepaired
CHD (59%) is 2:3 [1, 8, 9, 20, 21, 33, 34, 38, 42, 47, 58,
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65, 67, 68, 72, 74, 79, 83, 84, 88, 97, 99, 100, 107, 108,
110, 111, 116, 119, 122, 127, 137]. Surgical complete repair
may eliminate the IE risk [96], but implantation of
prosthetic material may increase risk for post-
interventional IE [117, 132]. Therefore, the cumulative
incidence of IE within 25 years following cardiac surgery
depends on the type of CHD: 0% for secundum type ASD,
patent ductus arteriosus, and pulmonary valve stenosis;
Fig. 3 Anatomic localization of infective endocarditis in congenital
heart disease. Percentages of distribution of the different anatomic
localization are calculated from the data of retrospective clinical
studies [1, 8, 9, 20, 21, 33, 34, 38, 42, 47, 53, 58, 65, 67–69, 72, 74,
79, 83, 84, 88, 97, 99, 100, 107, 108, 110, 111, 116, 119, 122, 127,
137]. Extracardiac manifestations include shunts, conduits, and
endarteritis in patent ductus arteriosus and coarctation of the aortic
arch. ASD atrial septal defect, AV aortic valve, CHD congenital heart
disease, CoA coarctation of the aortic arch, MV mitral valve, LA left
atrium, LV left ventricle, PDA patent ductus arteriosus, PV pulmonary
valve, RA right atrium, RV right ventricle, SAS subaortic stenosis, TV
tricuspid valve, VSD ventricular septal defect
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Table 1 Synopsis of IE associated or not with congenital heart disease in children and adults
Infective endocarditis not associated with congenital heart
disease
Infective endocarditis associated with congenital heart disease
Child (<18 years) Adult Child (<18 years) Adult
Pathogenesis Native valve endocarditis [24]
Comparable pathogenetic steps: (1) damage of valvular or mural endocardium; (2) development of NBTE; (3) microbial adherence to NBTE; (4) microbial
colonization, invasion, and replication within microbial thrombotic endocarditis; and (5) embolization of parts of microbial thrombotic endocarditis
Prosthetic valve endocarditis/cardiovascular device-related infection [11, 24]
Specific risk factors: (1) physical and chemical characteristics of foreign material [11], (2) pathogen virulence factors related to foreign material adherence
[11], (3) host response to foreign material [114], (4) biofilm formation [41], and (5) endothelial dysfunction due to shear stress [5, 75, 115]
NTBE de novo [95]: in neonates with
affection of right-sided normal
heart structures [91,
93, 94, 101]
NTBE de novo [95]: in IVDA
endocarditis
Specific risk factors [34, 46, 65, 88, 100,
108, 122]: (1) cyanotic
heart disease; (2) palliative shunts,
conduits, prosthesis; (3) age younger
2 years of age
Specific risk factors [65, 134]:
foreign material such as
palliative shunts, conduits,
prosthesis
Pathogens In healthcare-associated endocarditis
[24, 35, 91] predominance of
staphylococci, gram-negative
bacteria, and fungi [123]
Streptococcus spp. (40%) Streptococcus spp. (42%) Streptococcus spp. (46%)
In older children predominance
of S. aureus [36]
Staphylococcus spp. (40%) Staphylococcus spp. (26%) Staphylococcus spp. (28%)
Others (Enterococcus spp.,
fungi, HACEK) (15%)
Others (Enterococcus spp.,
fungi, HACEK) (16%)
Others (Enterococcus spp.,
fungi, HACEK) (16%)
Culture negative (5%) [24] Culture negative (14%) [1, 8,
21, 24, 42, 47, 53, 58, 67–
69, 84, 88, 99, 108, 110,
111, 116, 119]
Culture negative (10%) [9, 33,
34, 38, 65, 72, 74, 83, 97,
122, 127, 137]
Localization
of lesions
Rheumatic heart disease
[27, 70]: left-sided>
right-sided mitral valve
>aortic valve
Left-sided: mitral valve
(40%)>aortic valve (25%)
Left-sided: mitral valve (26%)
>aortic valve (16%)
Left-sided (60%): mitral valve
>aortic valve [38, 65, 97]
Right-sided: tricuspid valve
(<10%), pulmonary valve
(<5%), Other extracardiac
(<5%) in IVDA (>50%)
[24, 86]
Right-sided: tricuspid valve
(15%), pulmonary valve
(9%), other right-sided
(14%), extracardiac struc
tures (11%) [1, 38, 42, 65,
97, 111]
Right-sided (40%) [38, 65, 97]
Lifetime risk Rheumatic heart disease
[70]: risk of infective
endocarditis 6%,
females>males, mitral
valve predominantly
affected
Overall incidence: 1.5 to
6/100,000/year
Cyanotic (8.2/1,000 patients/
year)>non-cyanotic (1.7–2.4/
1,000 patients/year) tetralogy
of Fallot up to 25%
postoperative risk for IE
[32, 53]
Ventricular septal defect at an
age of 30 years: 10% lifetime
risk for IE. Adult IE is
associated with CHD in 5%
to 13% (bicuspid aortic valve
in>20% of adults) [24, 43]
Elevated lifetime risk: (1)
mitral valve prolaps (30%)
in younger patients, (2)
degenerative valvular
disease (20%) in older
patients, (3) hypertrophic
cardiomyopathy (5%), (4)
prosthetic valve (5–10%),
and (5) intracardiac
devices in IVDA: lifetime
risk 1–5% [24]
Episode-
related
complications
No data available Cardiac: CHF (40%),
PVA (35%),
Extracardiac: emboli, overall
(25%); cerebral (30%), renal
(20%), peripheral affections
(35%) [24]
Cardiac: CHF (30%), valvular
damage (30%), PVA (<5%),
arrhythmia (5%).
Extracardiac: emboli, overall
(20%); cerebral (15%), renal
(10%), peripheral affections
(<10%) [1, 8, 21, 24, 42, 47, 53, 58,
67–69, 84, 88, 99, 108, 110, 111, 116, 119]
Cardiac: CHF (25%), PVA (5–10%),
arrhythmia (5%).
Extracardiac: emboli, overall
(20%), cerebral (10%), renal
(5%), peripheral affections
(<10%) [9, 33, 34, 38, 65,
72, 74, 83, 97, 122, 127, 137]
Outcome No data available Overall mortality (10–30%)
[24]
Overall mortality (10%) [34, 65, 72, 79, 84,
97, 107, 135]
Overall mortality (10%) [65, 72, 135]
Surgical mortality (20%)
[102]
Surgical mortality (14%) [34, 59, 72, 86, 97]
Recurrence (<10%) Recurrence (<3%)
Early relapse (2–20%)
Late relapse (1–10%)
CHD congenital heart disease; CHF congestive heart failure; HACEK Haemophilus spp. Actinobacillus actinomycetemcomitans, Cardiobacterium
hominis, Eikenella corrodens, Kingella kingae; IVDA intravenous drug abuse; NBTE nonbacterial thrombotic endocarditis; PVA paravalvular abscess
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1.3% for tetralogy of Fallot; 2.7% for VSD; 2.8% for primum
type ASD; 3.5% for coarctation of aortic arch; and 13% for
aortic valve stenosis. A 20-year follow-up in transposition of
great arteries revealed a cumulative incidence of IE of 4.0%
and a 10-year follow-up in complete ASD of 1.1% and in
pulmonary atresia with intact ventricular septum of 5.3% and
with VSD of 6.4% [96]. Importantly, for risk assessment,
emphasis has to be put on prosthetic material and its impact
on cardiovascular device-related infections (Table 3) [8, 33,
34, 38, 53, 58, 65, 69, 72, 79, 83, 84, 88, 97, 108, 119, 137].
Palliated CHD
Patients with complex CHD with functionally univentricular
malformations have become treatable by cardiac surgery with
the Norwood and Fontan procedures (Fig. 1) [16, 34, 38, 65,
72, 83, 88, 97, 137]. Patients after univentricular palliation of
complex CHD with functional univentricular malformations
leading to bidirectional Glenn anastomosis and Fontan
procedure survive until adulthood but remain at lifetime risk
for IE due to frequent use of prosthetic material [34, 38, 65,
72, 83, 88, 97, 137]. Patients palliated by an aortopulmonary
shunt remain at lifetime risk as well [24, 134]. These patients
can be predicted to increasingly contribute to future numbers
of post-interventional IE, which currently account for >15%
(Fig. 3) [34, 38, 65, 72, 83, 88, 97, 137].
Prosthetic material
Increased IE risk following cardiac surgery [96] and
catheter-related cardiac interventions is mainly linked to
implantation of prosthetic material or cardiovascular devi-
ces, independent of underlying CHD [82, 83, 97, 118, 119].
The types of prosthetic material implanted with permanent
bloodstream contact are increasing (Table 3). Prosthetic
material is biological (animal or human heart valves,
sterilized by 1% glutaraldehyde and 20% isopropyl alcohol)
or non-biological (metal alloys or synthetic material used
for cardiovascular devices, such as stainless steel, platinum,
polytetrafluorethylene, pyrolytic carbon, polyvinyl chloride,
silicone, polydioxane, or polyglactic acid). Pacemaker
systems with intracardiac electrodes account for most cases
of intracardiac device-related IE [71]. Interventional closure
of ASD or VSD, stent implantation, or closure of patent
ductus arteriosus may also be followed by IE (Table 2) [14,
25, 26, 44, 54, 97, 104, 109, 117, 133]. Effects of various
foreign materials may differ considerably but have not been
properly studied in patients with CHD.
Sources of bacteremia
The risk of IE may be associated with various sources of
bacteremia. In adolescents with CHD, lifestyle habits such
as piercing, tattooing, nail biting, but also animal bites, skin
disorders such as acne, or intravenous drug abuse are
potential sources of bacteremia [7, 113]. IE by itself
predisposes in 2.7% for a second IE episode at the same
location [9]. Medical procedures, including dental care [8,
33, 34, 38, 42, 65, 68, 69, 72, 74, 83, 84, 88, 97, 99, 108,
116, 119, 122], cardiac surgery [8, 38, 65, 67–69, 72, 74,
83, 88, 97, 99, 108, 116, 119, 137], catheter-related
procedures [68, 69, 72, 83, 88, 97, 116, 119, 137], and
other non-cardiac invasive procedures [33, 38, 42, 65, 67–
69, 72, 74, 83, 84, 122, 137] are potential causes for
bacteremia in up to 46%, 18%, 20%, and 20% in cases of
CHD-associated IE, respectively. Until recently, antimicro-
bial prophylaxis was recommended for these procedures
[134]. Amoxicillin prophylaxis reduces bacteremia in
children after dental procedures from 84% to 33% [85].
Prophylaxis, however, may fail due to patient-related
factors (compliance) in up to 40%, physician-related factors
(knowledge) in 50%, and ineffective drugs against rare
pathogens in 66% [33, 38, 42, 65, 68, 69, 72, 73, 83, 84,
88, 97, 108, 116, 119, 122, 137]. Nowadays, bacteremia
from daily care activities is judged a far greater risk [134].
Other risk factors
Previous IE remains a substantial risk factor predisposing to
recurrent IE [134]. Age may be another risk factor as IE
peaks in infancy and late adolescence [36]. IE in preterms,
neonates, or infants younger than 2 years of age is related to
other risk factors than in older patients with CHD [35, 91,
101]. Leading risk factors are prematurity with immune
compromise and central venous access with catheter-related
blood stream infections [94]. Normal cardiac structures may
be affected, and the incidence of fungal IE is up to 10% [15,
36, 80, 93].
Recently, the life-long risk of infective endocarditis has
been determined for ACHD patients at an age of 18 years
during transition by complex statistical data analysis in a
nationwide Dutch registry. Risk factors such as gender, type
of CHD, and complications of CHD during childhood
(<18 years) were used to predict risk of IE at the end of the
fourth and sixth decade of life and to discriminate in a high
(≥3%) and low (<3%) risk patient population groups [128].
Microbiology
Most cases of CHD-associated IE are caused by Strepto-
coccus spp. (44%; 95% confidence interval (CI), 39.4–48.6,
as calculated from literature), including Streptococcus
viridans group (Streptococcus mutans, Streptococcus san-
guis, Streptococcus mitis) and Enterococcus spp. [8, 9, 21,
33, 38, 42, 47, 53, 58, 65, 67–69, 73, 74, 83, 84, 88, 97, 99,
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108, 110, 116, 119, 122, 127, 137] and by Staphylococcus
spp. (27%; 95% CI, 23.4–30.8; Staphylococcus aureus,
coagulase-negative staphylococci), the most frequently
(>50%) isolated organism in cardiovascular device-related
infections [11, 65]. Gram-negative HACEK group bacteria,
Haemophilus aphrophilus, Actinobacillus actinomycetemco-
mitans, Cardiobacterium hominis, Eikenella corrodens, and
Kingella kingae, or miscellaneous microorganisms and fungi
cause 16% (95% CI, 11.9–19.3) of cases. Culture-negative
IE is found in 12% (95% CI, 8.5–15.9). Gram-negative
Table 3 Catheter-based devices and surgery-based foreign material for the treatment of congenital heart disease
Treatment
modality
Device type Reasons for use of devices or foreign
material
Material involved
Catheter-
based
Closure
devices
Atrial septal defect Nitinol, 316L stainless steel, platinum, teflon, polyurethane, homologous
pericardium, ivalon, polyester fabric, polytetrafluorethylene, latex, nylon,
phynox, chromicum, nickel, titanium, molybdenum, cobalt
Patent foramen ovale
Patent ductus arteriosus
Ventricular septal defect
Paravalvular leaksb
Collateral blood vesselsc
Stentsa Branch pulmonary artery stenosis 316L stainless steel, platinum, iridium, nickel, titanium, molybdenum,
cobalt, tantalum, polytetrafluorethylene, bovine jugular veinCoarctation of the aorta
Patent ductus arteriosus
Patent foramen ovale
Systemic/pulmonary vein stenosis
Peripheral vascular disease/carotid
artery transcatheter valve repair
Miscellaneous Electrophysiological cardiac devicesd Polyvinyl chloride, stainless steel, titanium, nitinol
Ventricular assist devicese
Venous or arterial line
Vena caval filters
Ventriculoatrial shunts
Vascular closure devices
Peritoneal dialysis
Hemodialysis, filtration
Pledgets
Surgery-
based
Closure
device
Patches Homologous pericardium, polytetrafluorethylene, polyester fabric
Sutures Artificial or biological Polydioxanone, polyglactic acid, polyglycolic acid, polypropylene
Heart valves Mechanical
Biological (homograft, xenograft) Bovine jugular veinf
Vascular
conduit
Shunt Polytetrafluorethylene
Vascular
grafts
Biological vessel (veins and arteries)
Hemodialysis
Clips Extracardial/vascular Stainless steel
Tubes Drainage Polyvinyl chloride, silicone
a Including different type of stents such as bare metal, covered, drug eluting, biodegradable, stented valves, stent grafts
b Including perforated sinus of Valsalvae
c Including aortopulmonary collateral vessels in pulmonary atresia/tetralogy of Fallot; systemic artery to pulmonary collaterals and venovenous
collaterals after bidirectional Glenn and Fontan procedures; systemic arteriovenous fistulae such as vein of Galen malformation, hepatic
arteriovenous malformation, hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu syndrome); pulmonary arteriovenous fistulae; coronary
artery fistulae; aortopulmonary surgical shunts
d Including pacemaker, implantable cardioverter defibrillator, biventricular pacing/cardiac resynchronization therapy, pacing leads, pacemaker
generator
e Including extracorporeal membrane oxygenation, left ventricular assist devices, total artificial hearts, intra-aortic balloon counterpulsation
catheters
f Sterilized in 1% glutaraldehyde and 20% isopropyl alcohol
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bacteria are more frequent in IE associated with CHD
compared to adults with IE not associated with CHD [102,
121]. Therefore, the pathogen array in CHD contrasts that in
adult IE without CHD, where Staphylococcus spp. (40%)
dominates, followed by oral streptococci (31%), non-oral
streptococci (10%), and enterococci, or fungi (less than 10%
each; Table 1) [24].
Clinical manifestations and episode-related
complications
Clinical course
Clinical signs and symptoms of IE associated with CHD are
variable, insidious, and usually unspecific [28]. Two clinical
courses are distinguished: acute IE, a severe life-threatening
disease often characterized by fulminant onset, high rate of
complications leading to congestive heart failure (CHF), and
high rate of surgical intervention required for treatment, and
subacute IE which shows a subtle course, often blurred by
antibiotics [24, 77]. Subacute IE in children is associated
with cardiovascular device-related infections after catheter
interventional closure of ASD or VSD (Table 2) [8, 117]. The
calculated mean interval between assumed start of bacter-
emia and first symptoms of IE in CHD is approximately
2 weeks [72], similar to the adult IE not associated with
CHD caused by streptococci [120]. Only 16% of IE in CHD
are diagnosed during this “incubation period.” In the other
cases, diagnosis is delayed by 7–12 weeks [68, 72, 81].
Clinical signs and symptoms
The most frequent signs and symptoms of IE in CHD are
fever (>80%), often of low grade, malaise, fatigue, weight
loss or failure to thrive, splenomegaly, myalgia, arthralgia,
headache, chills, nausea, and vomiting [1, 8, 9, 20, 21, 33,
34, 38, 42, 47, 58, 65, 67, 68, 72, 74, 79, 83, 84, 88, 97, 99,
100, 107, 108, 110, 111, 116, 119, 122, 127, 137]. Specific
clinical findings are less frequent (<20%). They include
changing heart murmur or skin manifestations including
Osler nodes, Janeway lesions, or Splinter hemorrhages,
which are typical for IE, but can be observed in other
diseases such as lupus or typhoid fever. Fever while on
antibiotic therapy persists around 4.3 days, and blood
cultures become negative after 0.7 days [88].
Cardiac episode-related complications
Potential episode-related complications of IE in CHD may
localize inside or outside the heart [8, 9, 20, 21, 33, 34, 38,
42, 47, 53, 58, 65, 67–69, 72, 74, 79, 83, 84, 88, 97, 99,
107, 108, 110, 111, 119, 127, 137]. CHF occurs in up to
about half of the cases (range, 28–46%, as calculated from
literature) and is the leading cause of hemodynamic
compromise due to destruction of affected valves (22–
32%) [8, 9, 20, 21, 33, 34, 38, 42, 47, 53, 58, 65, 67–69,
72, 74, 79, 83, 84, 88, 97, 99, 107, 108, 110, 111, 119, 124,
127, 137]. Rarely, CHF in IE may result from emboli to
coronary arteries (<1%), myocarditis, arrhythmias (6–11%),
perivalvular abscess (PVA), myocardial abscess formation,
and intracardiac fistulae (0–7%) [3, 4, 8, 9, 20, 21, 33, 34,
38, 42, 47, 53, 58, 65, 67–69, 72, 74, 79, 83, 84, 88, 97, 99,
103, 107, 108, 110, 111, 119, 127, 137]. Involvement of
atrioventricular node may cause atrioventricular block in up
to 4% [8]. The frequency of episode-related complications
is comparable to adults with structural heart disease despite
their by far more frequent PVA [24, 40, 92]. As mortality
after surgery in acute IE is increased, indication and timing
of surgery are difficult to determine [105]. When myocar-
dial function is reduced, surgery should be done before
further hemodynamic deterioration occurs [96].
Extracardiac episode-related complications
Extracardiac episode-related complications of IE in CHD
patients are frequent (up to 43%) and either caused by
embolic events or immune phenomena [8, 9, 20, 21, 33, 34,
38, 42, 47, 53, 58, 65, 67–69, 72, 74, 79, 83, 84, 88, 97, 99,
107, 108, 110, 111, 119, 127, 137]. Infected heart valves
and contaminated cardiovascular devices such as electrodes
from pacemakers are sources of thromboemboli. No studies
compare risk for embolism in patients with and without
intracardiac devices. Episode-related complications are
more frequent in vegetations >10 mm in size and in left-
sided compared to right-sided vegetations [97], but not in
multiple vegetations [9, 79]. Embolic episodes frequently
lead to renal (10%), splenic (4%), pulmonary (28%),
cerebral (16%), bowel (4%), or peripheral vascular/cutane-
ous (26%) infarcts. Neurological episode-related complica-
tions (33%) including stroke (16%), seizures (11%), abscess
formation (5%), and hemiparesis (2%) may either constitute
initial manifestation of IE or manifest years after its
treatment.
Clinical signs and episode-related complications of
cardiovascular device-related infections are similar to those
of IE despite specific local and systemic clinical features
[11]. In percutaneously introduced devices, clinical signs
include local pain, induration, erythema, and purulent
drainage and in subcutaneously implanted devices include
cellulitis or abscess formation. Following pseudoaneurysm
formation involving the vascular graft, a pulsatile mass can
be detected on cardiac magnetic resonance imaging at site
of anastomosis. Following vegetation and thrombus forma-
tion on intra- or extracardiac devices, clinical complications
are embolisms to distal vessels either with direct vessel
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occlusion or indirect immune-mediated ischemia. In addi-
tion, signs of bacteremia may manifest [11].
Diagnosis
IE should be suspected in CHD patients with persisting
fever and newly manifesting CHF. Notably, IE in CHD after
cardiac surgery occurs after a mean interval of 5.2 to
8.8 years [72, 74]. A prompt diagnostic workup includes
repeated aerobe and anaerobe blood cultures, echocardiog-
raphy, and inflammation parameter determination, the
results of which are required for diagnosis of IE based on
the modified Duke criteria [82]. Modified Duke criteria
were shown useful also for diagnosis of IE in children
[108].
Blood cultures
Positive bacterial blood cultures are one of the key
indicators for diagnosis of IE. Their sensitivity in CHD-
associated IE is 82% [1, 8, 9, 20, 21, 33, 34, 38, 42, 47, 58,
65, 67, 68, 72, 74, 79, 83, 84, 88, 97, 99, 100, 107, 108,
110, 111, 116, 119, 122, 127, 137]. In patients treated with
antibiotics before blood collection, special blood culture
techniques including automated systems using resin to bind
antibiotics, thus facilitating bacterial growth despite anti-
biotics, should be used to avoid bias. Three sets of aerobe
and anaerobe cultures should be drawn. Reasonable blood
volumes are 1–3 ml for infants, 3–5 ml for toddlers and pre-
school-aged children, and 10 ml for school-aged children
and adolescents [31]. Persistently positive blood cultures,
defined as recovery of a microorganism consistent with IE,
are two blood culture sets drawn more than 12 h apart, all
three sets, or a majority of four or more separate blood
culture sets, with first and last drawn at least 1 h apart [82].
To detect “hard to grow” microorganisms (HACEK group
organisms or fungi) incubation should last 2–4 weeks
[23].
Echocardiography
The second key diagnostic indicator of IE is echocardiog-
raphy. Its sensitivity in CHD-associated IE is 60–80%, but
lower in complex types of CHD and in postoperative course
[8, 9, 20, 33, 34, 38, 53, 58, 79, 83, 84, 97, 107, 108, 127].
Diagnostic advantages of transesophageal echocardiogra-
phy such as more precise visualization of vegetations have
been validated for children [64]. Vegetations can be
visualized by two-dimensional echocardiography (transtho-
racic as small as 2–3 mm and transesophageal 1–1.5 mm)
[136]. The mean vegetation size is approximately 11.5 mm
[97]. Valvular regurgitation can be seen with color Doppler
echocardiography, and hemodynamic valvular compromise
with pulsed or continuous wave Doppler echocardiography
[55, 89, 90]. Moreover, echocardiography may visualize
myocardial abscess formation, paravalvular abscesses,
intracardiac fistulae, dehiscence of a prosthetic valve,
pericardial effusion, or severe myocardial dysfunction.
Guidelines for echocardiographic diagnosis of IE have
been published for adults [29, 56, 136] but not for children
with CHD, so far.
Intraoperative sampling
If surgery is required to replace infected valves or contami-
nated prosthetic material, samples for microbiological workup
should be collected including cultures and molecular diag-
nostics such as eubacterial (as a screening tool) and pathogen-
specific polymerase chain reaction assays [49].
Therapy
Antimicrobial therapy
In the mid-1940s, the introduction of penicillin changed IE
from an almost certainly fatal to a curable condition (Fig. 1)
[21, 30]. Treatment has become a multidisciplinary endeavor
involving specialists for cardiology, cardiac surgery, infec-
tious diseases, hematology, and other disciplines. Antimicro-
bial strategies must take two factors into account: (1)
Infecting organisms exist in a state of reduced metabolic
activity and are extremely densely packed inside vegetations
and (2) cure of IE requires sterilizing vegetations.
Bactericidal rather than bacteriostatic agents must be used
in high dosages and for sufficient time [131]. Combination of
a beta-lactam and an aminoglycoside results in synergistic
bactericidal effect [87]. Exceptions of this synergistic
bactericidal approach are modern bacteriostatic antibiotics
(linezolid or quinupristin/dalfopristin) [10].
Therapy should last >2 weeks, but causative microor-
ganism, involved valve, and antimicrobial compound used
must be taken into consideration. Antibiotics for 6 weeks or
even longer may be required in cardiovascular device-
related IE, which cannot be treated by surgery such as
explantation of foreign material due to comorbidity [62]. To
achieve higher serum drug levels, intravenous is preferable
to oral therapy.
Adequate antibiotic dosing is related to the minimal
inhibitory/bactericidal concentration of the compound
against isolated pathogens. Optimal dosing frequency,
interval, and administration procedure (bolus injection is
superior to continuous infusion) depend on microorganism
and antimicrobial agent used [17, 50]. Finally, timing of
therapy initiation is important. The danger of delaying therapy
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must be weighed against diagnostic importance of isolating
microorganisms in blood cultures. Guidelines for antibiotic
treatment of CHD-associated IE have been published by the
AHA [13, 46], European Society of Cardiology (ESC) [57],
and British Society for Antimicrobial Chemotherapy [45].
Cardiovascular device-related infections
Specific recommendations for cardiovascular device-related
infections have been published in the past [11] and recently
updated for cardiovascular implantable electronic device
infections by the AHA [11, 12] and by the ESC [57]. Thus,
since staphylococci are the most frequent pathogen,
treatment best follows recommendations for healthcare
associated IE or S. aureus IE (Table 2) [46]. Given the
possibility of methicillin resistance, an initial empiric
broad-spectrum therapy should include vancomycin until
susceptibility testing of isolated microorganisms is avail-
able. Linezolid or quinupristin/dalfopristin may be used in
patients with vancomycin intolerance/allergy or vancomycin-
resistant enterococci [6]. The combination of antibiotic
treatment with complete removal of contaminated device, if
ever possible, is preferred [11]. The device removal has been
proposed for closure devices of patent ductus arteriosus,
ASD, and VSD [11]. Similar recommendations are given for
peripheral arterial stent infections, apart from critical ill
children where surgical removal is associated with high risk
and therefore long-term antibiotic treatment is needed. [11]
Duration of antibiotic treatment in uncomplicated cases
is >14 days after device removal and first negative blood
culture, or 4 weeks in complicated cases with vegetations
on the device, and 6 weeks for cardiovascular device-
related infections in left ventricular assist devices compa-
rable to prosthetic cardiac valve infections [11]. A long-
term suppressive, even life-long antimicrobial therapy may
become necessary [106].
Fungal endocarditis
Fungal endocarditis remains difficult to treat, and mortality
approaches 50% [123]. Combined medical and surgical
therapy is recommended [13, 93]. After intravenous
antifungal therapy, it is often necessary to prevent an IE
relapse; this should involve an ongoing long-term antifungal
therapy, usually with an oral azole agent such as ketoconazole
[106], fluconazole, or voriconazole, depending on suscepti-
bility of fungi.
Microbiological monitoring during follow-up
Bacteremia may resolve within several days after initiation
of effective antimicrobials, and 75% of patients become
afebrile during first and 95% during second week of
adequate antibiotic therapy [24]. Fever persisting beyond
this period should trigger a repeated diagnostic workup,
although drug fever as a side effect of antibiotics has to be
considered. Blood cultures should be taken during, at the
end, and 4 weeks after completion of antibiotic treatment to
rule out recurrent IE [24].
Surgical management
Rates of surgery in pediatric patients with CHD-associated
IE, either during or after IE, are 16% to 67% [39, 72, 98].
Recommendations for time-optimized cardiovascular sur-
gery remain to be defined for patients with CHD-associated
IE [46]. Pre- and postoperative complications, mortality,
and length of hospital stay can be reduced, if surgery is
performed early during IE and uses reconstructive techni-
ques without foreign material [1, 61]. Risk-factor stratifi-
cation for death due to CHD-associated IE has not been
validated [59, 110, 111]. Nevertheless, surgery is considered
for ACHD patients with ongoing sepsis despite antimicro-
bial treatment, large mobile vegetations on echocardiogra-
phy with or without embolization, involvement of
mechanical valve prosthesis, myocardial abscess formation
suspicious for atrioventricular block, mycotic aneurysms,
and fungal endocarditis [48, 135]. This strategy is compa-
rable to that with IE not associated with CHD [105].
Development of IE after cardiac surgery such as shunt or
conduit procedure is a potentially life-threatening compli-
cation. Antimicrobial treatment alone is often insufficient
because prostheses are usually polytetrafluoroethylene
tubes which require a surgical re-intervention with explan-
tation of contaminated foreign material [96].
Prevention
The 2007 AHA revised guidelines for prevention of IE, the
ACC/AHA 2008 guidelines for management of adults with
CHD, and the 2009 guidelines of the ESC are focus on
underlying cardiac conditions associated with the highest
risk of adverse outcome and no longer on an increased
lifetime risk for IE [57, 130, 134]. Nevertheless, the AHA
stated difficulties determining contribution of a specific
CHD type as independent IE risk factor because the number
of published series of CHD-associated IE is limited. The
AHA guidelines recognize changes of management strate-
gies and their impact on the natural history of CHD. Indeed,
CHD is operated earlier during infancy and, therefore,
future numbers of patients with unrepaired CHD will
further decrease. Complete repair of certain CHD types,
such as VSD, eliminates the IE risk. Thus, the specific
focus of the AHA guidelines is conceivable: unrepaired
cyanotic CHD which is burdened with the highest risk for
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adverse outcome, including palliative shunts or conduits,
and repaired CHD with prosthetic material for at least
6 months following implantation, the period of incomplete
endothelialization with residual defects [134]. Nevertheless,
prospective studies have to carefully monitor the incidence
of IE, especially for unrepaired VSD, bicuspid aortic valve
stenosis, or patent ductus arteriosus, conditions for which
antibiotic prophylaxis is no longer recommended [18].
Outcomes
Overall mortality of CHD-associated IE has decreased to
10% in 1990 (Fig. 1) [34, 65, 72, 79, 84, 97, 107]. Progress
in diagnosing IE, improvements of antimicrobial treatment,
cardiac surgery, and catheter interventional therapy contrib-
uted to the decrease (Fig. 1). For comparison, mortality of
IE in adults with structural heart disease especially those
aged >60 years is up to 30% (Table 1) [59, 86]. Mortality of
surgery for IE remains high with 40% to 50% [34, 72, 97].
Sievert et al. reported a mortality of 1% due to
staphylococcal infection after interventional closure of
ASD [117], contrasting all other case studies or small
clinical series with no deaths related to IE (Table 2). Factors
predicting a worse outcome for IE in children CHD are
delay of hospital admission, age <3 years, and a vegetation
size >10 mm detected by echocardiography [2, 58, 79].
Conclusions
The risk for IE is distinct whether CHD is unrepaired,
repaired, or palliated. Management of CHD has changed in
the last 20 years. Most CHD have become treatable, and
CHD patients may survive until adulthood. Patients with
unrepaired CHD numerically decrease due to augmented
cardiac surgery or catheter interventional therapy early in
life. Concomitantly, patients with repaired CHD or palliated
CHD numerically increase. ACHD patients form a novel
patient group with distinct risk levels for IE throughout life.
Complete CHD repair may eliminate the risk for IE, as
exemplified in VSD. Residual defects after incomplete
CHD repair and palliated CHD retain an IE risk. The new
AHA and ESC guidelines focus on these patients.
In industrialized countries, IE in CHD is by far more
frequent than in RHD. IE in CHD may evolve after
implanting cardiovascular devices, and cardiovascular
device-related infections emerge as a new type of infection.
Streptococci are more frequently the cause than staphylo-
cocci except in cardiovascular device-related infections,
and IE localizes more often in the left than in the right
heart. Around half of the patients with CHD-associated IE
develop severe episode-related complications. Nevertheless,
the overall outcome of CHD-associated IE is better than of
IE not associated with CHD, possibly due to fewer
prosthetic valve endocarditis, S. aureus IE, co-morbidity,
or complications leading to (secondary) surgery.
Future directions
Prospective investigation of differences between children
and adults with CHD-associated IE is needed. For the
growing population of adults with CHD surviving until
middle age or longer, differences between IE associated
with versus without CHD may be more pronounced. As
adults with CHD may differ from adults with structural
heart disease regarding epidemiology, risk factors, clinical
presentation, complication rates, diagnosis, and outcome,
this will have to be carefully studied. Finally, the impact of
the new AHA and ESC IE prevention guidelines on IE
epidemiology in children and adults with CHD needs to be
monitored.
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